BioSpace looks at the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) for Alzheimer’s disease and Pfizer and BioNTech’s COVID-19 vaccine Comirnaty.
BioSpace reviews the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) as the first drug approved for Alzheimer’s disease in almost 20 years.
Massive layoffs could be headed to Biogen due to the disappointing rollout of the company’s Alzheimer’s drug Aduhelm that generated only a few million dollars in revenue over the past two quarters.
Following years of preparation, scientists from Brigham and Women’s Hospital are ready to start a clinical trial that will evaluate the use of an intranasal vaccine to prevent Alzheimer’s disease (AD).
Swiss pharma giant Roche announced a partnership with Shape Therapeutics valued at more than $3 billion that will attempt to harness the Seattle-based company’s RNA editing platform to take on neurodegenerative diseases as well as others.
GlaxoSmithKline Plc and U.S. firm Alector Inc. will together develop antibody-based treatments for Parkinson’s, Alzheimer’s and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on July 2.
Preliminary data from Annovis Bio’s Phase II study of ANVS401 shows significant cognitive improvements in Alzheimer’s patients after only one month of treatment.
Researchers from Albert Einstein’s College of Medicine are excited with the recently published findings of an experimental drug that reversed key symptoms of Alzheimer’s disease in mice.
Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.
Seattle-based Athira Pharma closed on a Series B financing worth $85 million, led by Perceptive Advisors.
